1月9日，阿拉丁盘中上涨2.06%，截至14:00，报13.38元/股，成交5261.50万元，换手率1.20%，总市值 44.50亿元。 资金流向方面，主力资金净流出159.14万元，大单买入1076.72万元，占比20.46%，卖出1235.87万元， 占比23.49%。 阿拉丁今年以来股价涨7.13%，近5个交易日涨7.13%，近20日涨2.61%，近60日涨6.44%。 截至9月30日，阿拉丁股东户数1.16万，较上期减少7.17%；人均流通股28729股，较上期增加7.72%。 2025年1月-9月，阿拉丁实现营业收入4.44亿元，同比增长17.59%；归母净利润5776.03万元，同比减少 20.41%。 分红方面，阿拉丁A股上市后累计派现2.41亿元。近三年，累计派现1.50亿元。 机构持仓方面，截止2025年9月30日，阿拉丁十大流通股东中，中欧医疗健康混合A（003095）、中欧 责任投资混合A（009872）、中欧行业成长混合(LOF)A（166006）退出十大流通股东之列。 责任编辑：小浪快报 资料显示，上海阿拉丁生化科技股份有限公司位于上海市浦东新区新金桥路36号南塔16楼，成立日期 ...

12月24日，阿拉丁盘中上涨2.06%，截至13:34，报12.86元/股，成交3020.19万元，换手率0.71%，总市 值42.77亿元。 分红方面，阿拉丁A股上市后累计派现2.41亿元。近三年，累计派现1.50亿元。 责任编辑：小浪快报 机构持仓方面，截止2025年9月30日，阿拉丁十大流通股东中，中欧医疗健康混合A（003095）、中欧 责任投资混合A（009872）、中欧行业成长混合(LOF)A（166006）退出十大流通股东之列。 资料显示，上海阿拉丁生化科技股份有限公司位于上海市浦东新区新金桥路36号南塔16楼，成立日期 2009年3月16日，上市日期2020年10月26日，公司主营业务涉及试剂的研发、生产及销售。主营业务收 入构成为：科研试剂96.96%，实验耗材2.15%，其他(补充)0.89%。 阿拉丁所属申万行业为：基础化工-化学制品-其他化学制品。所属概念板块包括：小盘、合成生物、猴 痘概念、熊去氧胆酸、电子商务等。 截至9月30日，阿拉丁股东户数1.16万，较上期减少7.17%；人均流通股28729股，较上期增加7.72%。 2025年1月-9月，阿拉丁实现营业收入4.44亿元，同比 ...

Core Viewpoint - Titan Technology's stock has experienced fluctuations, with a year-to-date increase of 23.83% but a recent decline over the past 20 and 60 days, indicating potential volatility in its market performance [1]. Financial Performance - For the period from January to September 2025, Titan Technology reported a revenue of 1.848 billion yuan, representing a year-on-year decrease of 13.06%. However, the net profit attributable to shareholders increased by 15.04% to 11.1678 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, Titan Technology had 9,293 shareholders, an increase of 20.41% from the previous period. The average number of circulating shares per shareholder decreased by 16.95% to 17,694 shares [2]. Business Overview - Titan Technology, established on October 18, 2007, and listed on October 30, 2020, is based in Shanghai and specializes in providing integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, and specialized chemicals. The main revenue sources are research reagents (42.70%), research instruments and consumables (28.42%), and specialized chemicals (26.48%) [1].

Company Overview - Titan Technology Co., Ltd. is located at 89 Shilong Road, Xuhui District, Shanghai, established on October 18, 2007, and listed on October 30, 2020 [1] - The company provides integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, smart laboratory equipment, research information technology, specialty chemicals, and related comprehensive technical services [1] Financial Performance - For the period from January to September 2025, Titan Technology achieved operating revenue of 1.848 billion yuan, a year-on-year decrease of 13.06% [2] - The net profit attributable to the parent company was 11.1678 million yuan, a year-on-year increase of 15.04% [2] - Cumulative cash dividends since the A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3] Stock Performance - As of December 1, Titan Technology's stock price increased by 2.14%, reaching 23.40 yuan per share, with a total market capitalization of 3.848 billion yuan [1] - Year-to-date, the stock price has risen by 28.78%, with a 4.09% increase over the last five trading days, a 4.29% decrease over the last 20 days, and a 10.52% decrease over the last 60 days [1] - The stock has a turnover rate of 0.70%, with a trading volume of 26.5661 million yuan [1] Shareholder Information - As of September 30, the number of shareholders increased by 20.41% to 9,293, while the average circulating shares per person decreased by 16.95% to 17,694 shares [2] Business Segments - The main business revenue composition includes: research reagents (42.70%), research instruments and consumables (28.42%), specialty chemicals (26.48%), laboratory construction and research information technology (2.37%), and others (0.02%) [1]

Group 1 - Aladdin plans to acquire a 35% stake in Shanghai Youke for 61.25 million yuan, which will make Shanghai Youke an associate company of Aladdin after the transaction [1] - The funding for the acquisition will come from Aladdin's own or raised funds, with a cash balance of 613 million yuan as of Q3 2025 and a net cash flow from operating activities of 159 million yuan for the first three quarters [1] - Shanghai Youke specializes in the R&D, production, sales, and service of general laboratory analytical instruments, with key products including UV-visible spectrophotometers and high-precision laboratory electronic balances [1][2] Group 2 - The acquisition aligns with Aladdin's core business in research reagents, allowing for synergistic opportunities such as bundled sales of instruments and reagents, enhancing customer retention [2] - Shanghai Youke's projected revenue and net profit for 2024 are 102 million yuan and 22.48 million yuan, respectively, with total assets of 162 million yuan and net assets of 95.88 million yuan at the end of 2024 [2] - The estimated valuation of Shanghai Youke's 100% equity is 175 million yuan, reflecting an 82.51% increase in net assets as of the end of 2024 [2] Group 3 - Aladdin has been actively pursuing investments and partnerships to expand its product line and business chain, completing six investment projects since 2023 [3] - The company reported a revenue of 169 million yuan for Q3 2025, a year-on-year increase of 21.26%, and a net profit of 29.30 million yuan, up 15.8% [3] - The domestic market for research reagents is experiencing accelerated competition due to the rapid improvement in the quality and variety of domestic products, enhancing the competitiveness of local manufacturers [3]

Group 1 - Aolide plans to raise no more than 300 million yuan through a simplified procedure for issuing shares to specific targets, with net proceeds allocated to the production base project for OLED display core materials and to supplement working capital [1] - Wanbang's subsidiary has obtained a 10-year exclusive agency for sildenafil oral suspension, which is suitable for patients with swallowing difficulties [2] - Titan Technology and its affiliate plan to jointly invest in increasing capital for its subsidiary, Micro Detection, raising its registered capital from 10 million yuan to 50 million yuan [3] Group 2 - Jindike will not issue new batches of quadrivalent influenza virus split vaccine this year, having produced approximately 1.56 million doses [4] - Aladdin intends to purchase 35% equity of Youke for 61.25 million yuan, funded by its own or raised capital [5] - Gujia Home's application for a private placement of A-shares has been approved by the Shanghai Stock Exchange [7] Group 3 - Honghe Technology's application for a private placement of A-shares has been approved by the China Securities Regulatory Commission [9] - Guangdian Yuntong has won contracts totaling 308 million yuan for the construction of an artificial intelligence application pilot base [10] - Shanghai Mechanical plans to repurchase B-shares worth no more than 278 million yuan [11] Group 4 - Weiling Co. is planning a change of control, with shares representing 7.76% of the total being transferred [14] - Jiugang Hongxing intends to invest 200 million yuan to establish a wholly-owned subsidiary focusing on high-quality special steel materials [16] - Zhongjian Technology has submitted an application for H-share listing [17] Group 5 - Sainuo Medical has received registration approval for its coronary product in Pakistan [18] - Huafeng Aluminum plans to acquire 100% equity of Huafeng Puen for 100 million yuan [20] - Fuda Co. intends to establish a wholly-owned subsidiary with an investment of 30 million yuan [22] Group 6 - Su Yan Jingshen's application for a private placement of shares has been approved by the Shanghai Stock Exchange [24] - Zhongchuang Co. has set the inquiry transfer price at 25.75 yuan per share [25] - Jinpu Garden has had a lawsuit involving 26.557 million yuan accepted by the court [29] Group 7 - ICBC has approved the appointment of Zhao Guid as vice president [30] - Betta Pharmaceuticals has had its drug registration application for ensartinib accepted [32] - Times New Materials plans to invest 6 million euros to establish a wholly-owned subsidiary in Serbia [34] Group 8 - China State Construction has appointed Chen Yong as vice president [36] - Dayang Electric plans to invest 10 million yuan to establish an industrial fund [38] - Advanced Digital has appointed Liu Zhigang as deputy general manager [39] Group 9 - Tianqi Co. plans to transfer 7% equity of Youqi Intelligent for 130 million yuan [40] - Xinguo has submitted an application for H-share issuance and listing [42] - Jinhongshun's shareholder has terminated a share reduction plan [43] Group 10 - Wanrun Co.'s actual controller plans to increase shareholding between 365 million yuan and 730 million yuan [44] - Suzhou High-tech plans to sell 47% equity of its medical device subsidiary for 604 million yuan [45] - Huayou Cobalt's subsidiary has signed a product supply agreement with Yiwei Lithium Energy for approximately 127,800 tons of materials [47] Group 11 - China Communications has won 10 important projects totaling approximately 2.539 billion yuan [49] - Nopushin plans to raise no more than 1.45 billion yuan through a private placement [50] - Yun Aluminum plans to acquire minority stakes in three subsidiaries for a total of 2.267 billion yuan [51] Group 12 - Xiamen Tungsten plans to establish a 500 million yuan merger fund with multiple parties [52] - Aotewei has signed a contract worth approximately 700 million yuan [54] - Hemai Co.'s shareholders plan to reduce their holdings by no more than 3% [56]

11月25日，阿拉丁盘中上涨2.05%，截至13:48，报12.95元/股，成交3396.51万元，换手率0.79%，总市 值43.07亿元。 资金流向方面，主力资金净流入196.49万元，大单买入848.84万元，占比24.99%，卖出652.35万元，占 比19.21%。 截至9月30日，阿拉丁股东户数1.16万，较上期减少7.17%；人均流通股28729股，较上期增加7.72%。 2025年1月-9月，阿拉丁实现营业收入4.44亿元，同比增长17.59%；归母净利润5776.03万元，同比减少 20.41%。 分红方面，阿拉丁A股上市后累计派现2.41亿元。近三年，累计派现1.50亿元。 机构持仓方面，截止2025年9月30日，阿拉丁十大流通股东中，中欧医疗健康混合A（003095）、中欧 责任投资混合A（009872）、中欧行业成长混合(LOF)A（166006）退出十大流通股东之列。 责任编辑：小浪快报 阿拉丁今年以来股价涨14.27%，近5个交易日跌3.14%，近20日涨5.46%，近60日跌17.83%。 资料显示，上海阿拉丁生化科技股份有限公司位于上海市浦东新区新金桥路36号南塔16楼，成立日 ...

Company Overview - Titan Technology Co., Ltd. is located at 89 Shilong Road, Xuhui District, Shanghai, established on October 18, 2007, and listed on October 30, 2020 [1] - The company provides integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, smart laboratory equipment, research information technology, specialty chemicals, and related comprehensive technical services [1] - The revenue composition of Titan Technology is as follows: research reagents 42.70%, research instruments and consumables 28.42%, specialty chemicals 26.48%, laboratory construction and research information technology 2.37%, and others 0.02% [1] Financial Performance - As of September 30, Titan Technology reported a total revenue of 1.848 billion yuan for the period from January to September 2025, a year-on-year decrease of 13.06% [2] - The net profit attributable to the parent company was 11.1678 million yuan, reflecting a year-on-year increase of 15.04% [2] - Cumulative cash dividends since the A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3] Stock Performance - On November 20, Titan Technology's stock price decreased by 2.01%, trading at 22.92 yuan per share, with a total market capitalization of 3.769 billion yuan [1] - The stock has seen a year-to-date increase of 26.14%, but has declined by 7.99% over the last five trading days, 8.14% over the last 20 days, and 18.26% over the last 60 days [1] - As of the latest data, the number of shareholders is 9,293, an increase of 20.41% from the previous period, while the average circulating shares per person decreased by 16.95% to 17,694 shares [2] Market Activity - The net outflow of main funds was 4.5418 million yuan, with large orders buying 4.3981 million yuan (16.17% of total) and selling 8.9399 million yuan (32.87% of total) [1] - Titan Technology is categorized under the basic chemicals industry, specifically in the chemical products sector, and is associated with concepts such as buybacks, margin financing, pension concepts, scientific instruments, and electronic chemicals [1]

Core Points - Aladdin's stock price decreased by 2.04% on November 17, trading at 13.42 CNY per share with a market capitalization of 4.464 billion CNY [1] - The company has seen an 18.42% increase in stock price year-to-date, with a 1.51% rise over the last five trading days and an 11.37% increase over the last 20 days, but a 13.36% decline over the last 60 days [2] - Aladdin's main business involves the research, production, and sales of reagents, with 96.96% of revenue coming from scientific reagents [2] - As of September 30, 2025, Aladdin reported a revenue of 444 million CNY, a year-on-year increase of 17.59%, while net profit attributable to shareholders decreased by 20.41% to 57.76 million CNY [2] Financials - The company has distributed a total of 241 million CNY in dividends since its A-share listing, with 150 million CNY distributed over the last three years [3] - As of September 30, 2025, the number of shareholders decreased by 7.17% to 11,600, while the average circulating shares per person increased by 7.72% to 28,729 shares [2] Shareholder Information - The top ten circulating shareholders have seen changes, with several funds exiting the list as of September 30, 2025 [3]

Company Overview - Titan Technology Co., Ltd. is located at 89 Shilong Road, Xuhui District, Shanghai, established on October 18, 2007, and listed on October 30, 2020 [1] - The company provides integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, smart laboratory equipment, research information technology, specialty chemicals, and related comprehensive technical services [1] Financial Performance - For the period from January to September 2025, Titan Technology achieved operating revenue of 1.848 billion yuan, a year-on-year decrease of 13.06% [2] - The net profit attributable to the parent company was 11.1678 million yuan, representing a year-on-year increase of 15.04% [2] - Cumulative cash dividends since the A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3] Stock Performance - As of November 12, Titan Technology's stock price decreased by 2.15%, trading at 24.13 yuan per share, with a total market capitalization of 3.968 billion yuan [1] - Year-to-date, the stock price has increased by 32.80%, with a slight increase of 0.54% over the last five trading days, but a decline of 0.33% over the last 20 days and 13.33% over the last 60 days [1] - The number of shareholders as of September 30 was 9,293, an increase of 20.41% from the previous period, while the average circulating shares per person decreased by 16.95% to 17,694 shares [2] Business Segmentation - The main business revenue composition includes: research reagents (42.70%), research instruments and consumables (28.42%), specialty chemicals (26.48%), laboratory construction and research information technology (2.37%), and others (0.02%) [1] - Titan Technology is classified under the Shenwan industry as basic chemicals - chemical products - other chemical products, and is associated with concepts such as share buybacks, margin financing, electronic chemicals, pension concepts, and scientific instruments [1]